• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease.

作者信息

Sun Qi, Ye Fei, Liang Hao, Liu Hongbo, Li Chunmei, Lu Roujian, Huang Baoying, Zhao Li, Tan Wenjie, Lai Luhua

机构信息

BNLMS, Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University, Beijing, China.

NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China.

出版信息

Signal Transduct Target Ther. 2021 May 29;6(1):212. doi: 10.1038/s41392-021-00628-x.

DOI:10.1038/s41392-021-00628-x
PMID:34052830
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8164054/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032e/8164628/ae820fbd45ff/41392_2021_628_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032e/8164628/ae820fbd45ff/41392_2021_628_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032e/8164628/ae820fbd45ff/41392_2021_628_Fig1_HTML.jpg

相似文献

1
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease.巴多昔芬和巴多昔芬甲酯是两种正在进行临床试验的Nrf2激活剂，它们可抑制新型冠状病毒（SARS-CoV-2）的复制及其3C样蛋白酶。
Signal Transduct Target Ther. 2021 May 29;6(1):212. doi: 10.1038/s41392-021-00628-x.
2
Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.靶向冠状病毒 3C 样主蛋白酶的抗病毒候选药物概述。
FEBS J. 2021 Sep;288(17):5089-5121. doi: 10.1111/febs.15696. Epub 2021 Feb 1.
3
Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.靶向 SARS-CoV-2 主蛋白酶：一项计算药物再利用研究。
Arch Med Res. 2021 Jan;52(1):38-47. doi: 10.1016/j.arcmed.2020.09.013. Epub 2020 Sep 17.
4
extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease .黄芩提取物和黄芩素抑制 SARS-CoV-2 及其 3CL 样蛋白酶的复制。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):497-503. doi: 10.1080/14756366.2021.1873977.
5
3-chymotrypsin-like protease in SARS-CoV-2.SARS-CoV-2 中的 3-糜蛋白酶样蛋白酶。
Biosci Rep. 2024 Aug 28;44(8). doi: 10.1042/BSR20231395.
6
QSAR Modeling of SARS-CoV M Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2.SARS-CoV M 抑制剂的定量构效关系建模将苏法戈利昔、西尼利尤单抗、普罗格来米特辛和其他药物鉴定为抗 SARS-CoV-2 再利用的候选药物。
Mol Inform. 2021 Jan;40(1):e2000113. doi: 10.1002/minf.202000113. Epub 2020 Aug 24.
7
Potential SARS-CoV-2 protease M inhibitors: repurposing FDA-approved drugs.潜在的 SARS-CoV-2 蛋白酶 M 抑制剂：重新利用 FDA 批准的药物。
Phys Biol. 2021 Feb 9;18(2):025001. doi: 10.1088/1478-3975/abcb66.
8
In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.计算机模拟研究评估新型冠状病毒（COVID-19）和 SARS-CoV 的 3C 样蛋白酶的新型结构的抗病毒活性。
Med Chem. 2021;17(4):380-395. doi: 10.2174/1573396316999200727125522.
9
Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.感染后用蛋白酶抑制剂治疗可提高致死性 SARS-CoV-2 感染小鼠的存活率。
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29). doi: 10.1073/pnas.2101555118.
10
Advances Toward COVID-19 Therapies Special Issue.《COVID-19治疗进展》特刊。
J Med Chem. 2022 Feb 24;65(4):2713-2715. doi: 10.1021/acs.jmedchem.2c00178. Epub 2022 Feb 9.

引用本文的文献

1
Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt.类风湿关节炎中新出现的治疗靶点：聚焦于缺氧诱导因子-1α、核因子E2相关因子2、信号转导和转录激活因子以及维甲酸相关孤儿受体γt
Curr Drug Targets. 2025;26(8):507-533. doi: 10.2174/0113894501372670250408074908.
2
Autocatalytic, Brain Tumor-Targeting Delivery of Bardoxolone Methyl Self-Assembled Nanoparticles for Glioblastoma Treatment.用于胶质母细胞瘤治疗的巴多昔芬甲基自组装纳米颗粒的自催化脑肿瘤靶向递送
Small Sci. 2024 May 22;4(8):2400081. doi: 10.1002/smsc.202400081. eCollection 2024 Aug.
3
Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth.

本文引用的文献

1
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.针对 SARS-CoV-2 蛋白酶和聚合酶的 COVID-19 治疗：现状和未来机遇。
J Med Chem. 2022 Feb 24;65(4):2716-2746. doi: 10.1021/acs.jmedchem.0c01140. Epub 2020 Nov 13.
2
Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges.利用药物再利用对抗 COVID-19-疗效、局限性和挑战。
Life Sci. 2020 Oct 15;259:118275. doi: 10.1016/j.lfs.2020.118275. Epub 2020 Aug 17.
3
Can Activation of NRF2 Be a Strategy against COVID-19?
机器学习辅助发现的T790M突变型表皮生长因子受体抑制剂CDDO-Me可有效抑制非小细胞肺癌生长。
Cell Commun Signal. 2024 Dec 5;22(1):585. doi: 10.1186/s12964-024-01954-7.
4
Non-electrophilic NRF2 activators promote wound healing in human keratinocytes and diabetic mice and demonstrate selective downstream gene targeting.非亲电 NRF2 激活剂促进人角质形成细胞和糖尿病小鼠的伤口愈合，并表现出选择性的下游基因靶向。
Sci Rep. 2024 Oct 24;14(1):25258. doi: 10.1038/s41598-024-75786-3.
5
Sulforaphane's Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)-Dependent and -Independent Mechanism of Anti-SARS-CoV-2 Activity.萝卜硫素抗SARS-CoV-2活性的核因子红细胞2相关因子2（Nrf2）依赖性和非依赖性机制。
J Respir Biol Transl Med. 2024 Sep;1(3). doi: 10.35534/jrbtm.2024.10010. Epub 2024 Jun 24.
6
Macrophage ILF3 promotes abdominal aortic aneurysm by inducing inflammatory imbalance in male mice.巨噬细胞 ILF3 通过诱导雄性小鼠炎症失衡促进腹主动脉瘤。
Nat Commun. 2024 Aug 23;15(1):7249. doi: 10.1038/s41467-024-51030-4.
7
Breaking the Chain: Protease Inhibitors as Game Changers in Respiratory Viruses Management.打破链条：蛋白酶抑制剂在呼吸道病毒管理中的变革作用。
Int J Mol Sci. 2024 Jul 25;25(15):8105. doi: 10.3390/ijms25158105.
8
[3-O-β-chacotriosyl glycyrrhetinic acid derivatives as potential small-molecule SARS-CoV-2 fusion inhibitors against SARS-CoV-2 entry into host cells].[3-O-β-查考三糖基甘草次酸衍生物作为潜在的小分子SARS-CoV-2融合抑制剂以阻止SARS-CoV-2进入宿主细胞]
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Mar 20;44(3):474-483. doi: 10.12122/j.issn.1673-4254.2024.03.08.
9
Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro.Bardoxolone 甲基通过激活 Nrf2 通路抑制体外狂犬病病毒的感染。
Virol J. 2023 Nov 10;20(1):258. doi: 10.1186/s12985-023-02213-w.
10
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.SARS-CoV 和 SARS-CoV-2 主要蛋白酶的结构与功能及其抑制作用：全面综述。
Eur J Med Chem. 2023 Nov 15;260:115772. doi: 10.1016/j.ejmech.2023.115772. Epub 2023 Aug 28.
NRF2 的激活能否成为对抗 COVID-19 的一种策略？
Trends Pharmacol Sci. 2020 Sep;41(9):598-610. doi: 10.1016/j.tips.2020.07.003. Epub 2020 Jul 14.
4
The Cysteinome of Protein Kinases as a Target in Drug Development.蛋白激酶半胱氨酸组作为药物开发的靶点。
Angew Chem Int Ed Engl. 2018 Apr 9;57(16):4372-4385. doi: 10.1002/anie.201707875. Epub 2018 Feb 2.
5
Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors.在晚期实体瘤中进行的合成三萜类化合物 2-氰基-3,12-二氧代-1,9-二烯-28-酸（CDDO）的 I 期研究。
Cancer Chemother Pharmacol. 2012 Feb;69(2):431-8. doi: 10.1007/s00280-011-1712-y. Epub 2011 Jul 31.